GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » Cyclically Adjusted PB Ratio

Akebia Therapeutics (STU:AX9) Cyclically Adjusted PB Ratio : 0.35 (As of May. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-27), Akebia Therapeutics's current share price is €1.008. Akebia Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.86. Akebia Therapeutics's Cyclically Adjusted PB Ratio for today is 0.35.

The historical rank and industry rank for Akebia Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:AX9' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.09   Med: 0.35   Max: 0.66
Current: 0.35

During the past years, Akebia Therapeutics's highest Cyclically Adjusted PB Ratio was 0.66. The lowest was 0.09. And the median was 0.35.

STU:AX9's Cyclically Adjusted PB Ratio is ranked better than
77.79% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs STU:AX9: 0.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Akebia Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €-0.120. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Akebia Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Akebia Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Cyclically Adjusted PB Ratio Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.18 0.38

Akebia Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.29 0.37 0.38 0.59

Competitive Comparison of Akebia Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Akebia Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted PB Ratio falls into.



Akebia Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Akebia Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.008/2.86
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Akebia Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.12/131.7762*131.7762
=-0.120

Current CPI (Mar. 2024) = 131.7762.

Akebia Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.415 100.560 5.786
201409 4.343 100.428 5.699
201412 4.144 99.070 5.512
201503 4.270 99.621 5.648
201506 4.620 100.684 6.047
201509 4.288 100.392 5.629
201512 3.922 99.792 5.179
201603 3.970 100.470 5.207
201606 3.121 101.688 4.044
201609 2.346 101.861 3.035
201612 1.672 101.863 2.163
201703 0.737 102.862 0.944
201706 1.194 103.349 1.522
201709 1.774 104.136 2.245
201712 2.175 104.011 2.756
201803 2.811 105.290 3.518
201806 2.496 106.317 3.094
201809 2.141 106.507 2.649
201812 4.782 105.998 5.945
201903 4.280 107.251 5.259
201906 3.869 108.070 4.718
201909 3.572 108.329 4.345
201912 2.920 108.420 3.549
202003 2.754 108.902 3.332
202006 2.297 108.767 2.783
202009 1.883 109.815 2.260
202012 1.375 109.897 1.649
202103 1.133 111.754 1.336
202106 0.854 114.631 0.982
202109 0.668 115.734 0.761
202112 0.370 117.630 0.414
202203 0.129 121.301 0.140
202206 0.321 125.017 0.338
202209 0.076 125.227 0.080
202212 0.027 125.222 0.028
202303 -0.072 127.348 -0.075
202306 -0.132 128.729 -0.135
202309 -0.196 129.860 -0.199
202312 -0.144 129.419 -0.147
202403 -0.120 131.776 -0.120

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Akebia Therapeutics  (STU:AX9) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Akebia Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (STU:AX9) Business Description

Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines